Abiraterone acetate in metastatic castration-resistant prostate cancer – the unanticipated real-world clinical experience

BACKGROUND: There is much interest in confirming whether the efficacy of abiraterone acetate (AA) demonstrated within the trial setting is reproducible in routine clinical practice. We report the clinical outcome of metastatic castration-resistant prostate cancer (mCRPC) patients treated with AA in...

Descripción completa

Detalles Bibliográficos
Autores principales: Poon, Darren M. C., Chan, Kuen, Lee, S. H., Chan, T. W., Sze, Henry, Lee, Eric K. C., Lam, Daisy, Chan, Michelle F. T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4802641/
https://www.ncbi.nlm.nih.gov/pubmed/27001043
http://dx.doi.org/10.1186/s12894-016-0132-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4802641/
https://www.ncbi.nlm.nih.gov/pubmed/27001043
http://dx.doi.org/10.1186/s12894-016-0132-z

Ejemplares similares